Assessing payment adequacy and updating payments: outpatient dialysis services

Nancy Ray and Andy Johnson
December 7, 2018
Overview of outpatient dialysis services, 2017

- Outpatient dialysis services used to treat individuals with end-stage renal disease
- FFS beneficiaries: About 394,000
- Providers: About 7,000 facilities
- Medicare FFS dialysis spending: $11.4 billion

Source: MedPAC analysis of 2017 100 percent claims submitted to dialysis facilities to CMS and CMS’s Dialysis Compare files.

Data are preliminary and subject to change.
Payment adequacy factors

- Beneficiaries’ access to care
  - Supply and capacity of providers
  - Volume of services
  - Dialysis marginal profitability
- Changes in the quality of care
- Providers’ access to capital
- Payments and costs
Dialysis capacity continues to increase

- Between 2016 and 2017, dialysis treatment stations increased by 3%; capacity growth exceeded beneficiary growth (0.4%)
- Net increase in number of facilities (about 250)
  - Few facilities closed in 2016; closed facilities (about 40) were more likely to be smaller, nonprofit, and hospital-based compared to all facilities
  - Analysis suggests that beneficiaries affected by closures (about 0.3%) received care at other facilities

Source: MedPAC analysis of 2012-2017 100 percent claims submitted by dialysis facilities to CMS. Data are preliminary and subject to change.
Growth in beneficiaries and dialysis treatments

- Between 2016 and 2017, the total number of dialysis FFS beneficiaries, total number of dialysis treatments, and average (non-annualized) treatments per beneficiary remained steady
  - Declining incidence rate of ESRD
  - Declining share of prevalent ESRD patients in FFS Medicare
  - Greater uniformity in paying for three dialysis sessions per week
- 17% marginal profit suggests that providers have a financial incentive to continue to serve Medicare beneficiaries
Use of dialysis drugs declined under the PPS (holding price constant)

Note: Dollars per treatment calculated by multiplying drugs units reported on claims by 2018 average sales price. Drugs included are: epoetin alfa, epoetin beta, darbepoetin (ESAs); iron sucrose, sodium ferric gluconate, ferumoxytol, ferric carboxymaltose (iron agents); calcitriol, doxercalciferol, paricalcitol (vitamin D agents); daptomycin, vancomycin, alteplase, and levocarnitine (all other drugs). ESAs (erythropoietin stimulating agents).

Source: MedPAC analysis of 2007-2017 100 percent claims submitted by dialysis facilities to CMS. Data are preliminary and subject to change.
Dialysis quality between 2012 and 2017

- Percent of dialysis FFS beneficiaries meeting guidelines for dialysis adequacy remains high
- Modest decrease in:
  - Admissions per beneficiary from 1.7 to 1.5
  - Readmissions from 22% to 21%
- Home dialysis increase from 9.5% to 11.0%
- Percent of beneficiaries with ED visit increased from 10% to 12%

Source: MedPAC analysis of Medicare claims and enrollment data. Results are unadjusted for differences in patient characteristics over time period. Data are preliminary and subject to change.
Providers’ access to capital

- Increasing number of facilities that are for-profit and freestanding
- Both large and small multi-facility organizations have access to private capital to fund acquisitions
- Under the dialysis PPS, two largest dialysis organizations have grown through acquisitions and mergers with mid-sized dialysis organizations
- 2017 all payer margin estimated at 23%

Data are preliminary and subject to change.
## 2017 Medicare margin

<table>
<thead>
<tr>
<th>Type of freestanding dialysis facility</th>
<th>Medicare margin</th>
<th>% of freestanding dialysis facilities</th>
<th>% of total freestanding dialysis treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>-1.1%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Urban</td>
<td>-0.4</td>
<td>82</td>
<td>88</td>
</tr>
<tr>
<td>Rural</td>
<td>-5.5</td>
<td>18</td>
<td>12</td>
</tr>
<tr>
<td>Treatment volume (quintile)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowest</td>
<td>-21.3</td>
<td>20</td>
<td>7</td>
</tr>
<tr>
<td>Second</td>
<td>-10.6</td>
<td>20</td>
<td>12</td>
</tr>
<tr>
<td>Third</td>
<td>-3.4</td>
<td>20</td>
<td>17</td>
</tr>
<tr>
<td>Fourth</td>
<td>0.8</td>
<td>20</td>
<td>24</td>
</tr>
<tr>
<td>Highest</td>
<td>5.4</td>
<td>20</td>
<td>39</td>
</tr>
</tbody>
</table>

Note: Freestanding dialysis facilities furnish 95 percent of all Medicare FFS dialysis treatments.
Source: MedPAC analysis of 2017 freestanding dialysis cost reports and 2016 100 percent claims submitted by dialysis facilities to CMS.
Projected Medicare margin in 2019

Payment factors considered:

- 2018 factors
  - Net payment update of 0.3% based on Protecting Access to Medicare Act of 2014, which reduced 2018 statutory update by 1 percentage point to reflect lower drug use
  - Regulatory changes to increase total payments by 0.2%
  - QIP reduce total payments by 0.14%

- 2019 factors
  - Net payment updates of 1.3%
  - Regulatory changes to increase total payments by 0.3%
  - QIP reduce total payments by 0.15% in 2019

Data are preliminary and subject to change
Policy changes in 2020

- Statutory update in 2020 is market basket less a productivity adjustment, which is currently estimated at 1.9%
- CMS projected a QIP reduction of total ESRD payments of 0.35%
- CMS will begin to pay facilities separately for all new drugs without any offset to the PPS base payment rate
Summary of payment adequacy

- Capacity is increasing
- Access to care indicators are favorable
- Dialysis quality improving for most measures
- Access to capital is robust
- 2017 Medicare margin: −1.1%

Data are preliminary and subject to change.